Evidence map›Paper›PMID 40580943›Full record

ArticleGenome biology and evolution2025

Fitness Effect of the Isoniazid Resistance Mutation S315T of the Catalase-Peroxidase Enzyme KatG of Mycobacterium tuberculosis.

Ugo Bastolla, Mikhail Rotkevich, Miguel Arenas, Manuel Arrayás, Marine Dogonadze, Anastasia Lavrova, Jorge Molina-Sejas, Michaël Tadesse, Ramón Xulvi-Brunet, Jonathan A G Cox and 3 more

Abstract read
In one paragraph

Article in Genome biology and evolution, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Molecular Mechanisms Underlying Antimicrobial Resistance in Mycobacteria.International journal of molecular sciences · 2026
    Review
  2. Anti-TB Drugs for Drug-Sensitive and Drug-ResistantCurrent issues in molecular biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ugo BastollaCentro de Biología Molecular Severo Ochoa (CSIC-Universidad Autónoma de Madrid), Madrid, Spain.ORCID 0000-0001-9342-4678
Mikhail RotkevichCentre for Genome Regulation, Barcelona, Spain.ORCID 0000-0002-1650-7688
Miguel ArenasDepartment of Biochemistry, Genetics and Immunology and CINBIO, Universidade de Vigo, 36310 Vigo, Spain.ORCID 0000-0002-0516-2717
Manuel ArrayásÁrea de Electromagnetismo, Universidad Rey Juan Carlos, 28933 Móstoles, Spain.ORCID 0000-0003-2225-6966
Marine DogonadzeSaint-Petersburg State Research Institute of Phthisiopulmonology, Saint-Petersburg, Russia.ORCID 0000-0002-9161-466X
Anastasia LavrovaSaint-Petersburg State University, Saint-Petersburg, Russia.ORCID 0000-0002-8969-535X
Jorge Molina-SejasCentro de Biología Molecular Severo Ochoa (CSIC-Universidad Autónoma de Madrid), Madrid, Spain.
Michaël TadesseUniversity of Warwick, Warwick, UK.ORCID 0000-0002-6891-0401
Ramón Xulvi-BrunetDepartamento de Física, Escuela Politécnica Nacional, Quito, Ecuador.ORCID 0000-0002-6013-4831
Jonathan A G CoxAston University, Birmingham, UK.ORCID 0000-0001-5208-4056
Dmitry NerukhAston University, Birmingham, UK.ORCID 0000-0001-9005-9919
Natalia González-BenítezDepartamento de Biología y Geología, Física y Química Inorgánica, Universidad Rey Juan Carlos, 28933 Móstoles, Spain.ORCID 0000-0003-0240-8221
Michael StichDepartamento de Matemática Aplicada, Ciencia y Tecnología de los Materiales y Tecnología Electrónica, Universidad Rey Juan Carlos, 28933 Móstoles, Spain.ORCID 0000-0001-8862-1044

Funding

European Union's Horizon 2020Innovation Staff ExchangeMarie Sklodowska-Curie ResearchMSCA-RISE-2018 823922
6 · The paper itself

Abstract

The mutation S315T of the catalase-peroxidase (CP) protein KatG of Mycobacterium tuberculosis is the most common mutation that confers resistance to the prodrug isoniazid. Here, we reconstruct its evolutionary history in 145 whole-genome sequences of M. tuberculosis from Russian hospitals, inferring 11 independent appearances of this mutation and 5 reversion events, with an estimated reversion rate 1,500 times higher than the rate of preserved nonsynonymous or intragenic mutations. This suggests that, contrary to the commonly held view, the mutation KatG(S315T) results in a fitness cost, possibly because of reduced tolerance to oxidative stress. Consistent with this interpretation, the mutant enzyme presents reduced CP activities. Applying the torsional network model (TNM), we found that the mutant protein shows more restricted thermal dynamics, although its functional site moves quite similarly to the wild type. Of the four internal clones where KatG(S315T) arose, two present high reproductive rates and secondary mutations at the 5'-UTR region of the gene encoding superoxide dismutase A (sodA), while the other two present significantly lower reproductive rates and lack mutations at genes related with tolerance to oxidative stress. Our results suggest that the resistance mutation KatG(S315T) incurs a fitness cost, which may be alleviated through compensatory mutations at the gene sodA or other genes that respond to oxidative stress, such as the previously known gene ahpC. This suggests that isoniazid treatment could be complemented with drugs that produce oxidative stress in order to hinder the propagation of resistant strains devoid of compensatory mutations.

Indexed as

Bacterial ProteinsCatalaseDrug Resistance, BacterialIsoniazidMycobacterium tuberculosisAntitubercular AgentsEvolution, MolecularGenetic FitnessMutationOxidative StressAntitubercular AgentsBacterial ProteinsCatalaseIsoniazidkatG protein, Mycobacterium tuberculosisantimicrobial resistanceisoniazidMycobacterium tuberculosisoxidative stressregularized maximum likelihood and minimum evolution (REGMLAME)S315T

Identifiers

PMID40580943
PMCPMC12242383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.